Non-Muscle Invasive Bladder Cancer

View All

Pharma News for CG Oncology, Amgen, Elevar, and GSK
CG Oncology Teams Up With Merck & BMS; Parse Biosciences Partners With Molecular Diagnostics Korea; Amgen’s Olpasiran; Elevar Therapeutics Announces Results of Rivoceranib; FDA Approves GSK’s Measles Vaccine; Sage & Biogen Reveals Postpartum Depression Trial Result

FDA Gives Green Signal to First Measles Vaccine in Almost 50 Years GSK announced that the company's vaccine for protection against mumps, measles, and rubella (MMR) had been approved by the U.S. FDA. According to data from six clinical studies, the company filed a Biologics License Application in August 2021. ...

Find More

NMIBC Market Size | NMIBC Market Drivers and Barriers
Market Drivers and Barriers That Will Shape The NMIBC Market In The Next Ten Years

After 40 years of the introduction of the BCG immunotherapy, it continues to remain as the gold standard of the treatment of Non-muscle invasive bladder cancer (NMIBC). However, BCG intravesical therapy fails to yield responses in more than 50% of the NMIBC patients. After a shocking failure of BCG, cystectomy is p...

Find More